NCT05634512
Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.
StatusActive, Not Recruiting
PhaseNot specified
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 4 words
- Study completion pushed from Oct 1, 2026 to Oct 1, 2027
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 24 to confirmed 13
- Primary completion date changed from estimate of Oct 1, 2025 to Oct 28, 2025
- Site details revised
- Notable Primary completion date: Oct 1, 2024 to Oct 1, 2025
- Study completion date: Oct 1, 2025 to Oct 1, 2026
- Minor Trial status: Enrolling by Invitation to Recruiting
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Identify covariates that impact drug exposure
Timeframe: 2 years
Identify key differences pre- and post-HCT leading to variability in PK parameters
Timeframe: 2 years
Arms and interventions
Collect blood from patients with MPS-IH) undergoing laronidase therapy and stem cell transplant.
The primary aim is to characterize the PK of IV laronidase in individuals with MPS IH and identify patient specific covariates that impact drug exposure. The secondary aim is to identify key differences pre-and post-HCT leading to variability in PK parameters for patients receiving IV laronidase therapy for the treatment of MPS-IH.
Drugs: Laronidase therapy and a stem cell transplant
Sites
1 site in 1 country
- University of Minnesota Masonic Cancer CenterMinneapolis, Minnesota, United States